Kymera Therapeutics, Inc. 公司旗下药物KT-621的扩大性1b期特应性皮炎试验结果显示,在100毫克与200毫克剂量组中均实现了深度STAT6降解,皮肤与血液中的降解率中位数分别达到94%和98%。
Kymera Therapeutics盘前暴涨超31%。
Kymera Therapeutics, Inc. 公司旗下药物KT-621的扩大性1b期特应性皮炎试验结果显示,在100毫克与200毫克剂量组中均实现了深度STAT6降解,皮肤与血液中的降解率中位数分别达到94%和98%。
Kymera Therapeutics盘前暴涨超31%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.